Revenue: As of FY2026 Q1, the actual value is USD 65.84 M, beating the estimate of USD 53 M.EPS: As of FY2026 Q1, the actual value is USD -0.02, beating the estimate of USD -0.0875.EBIT: As of FY2026 Q1, the actual value is USD 1.718 M.<h3>Financial Performance Overview</h3>Maravai LifeSciences Holdings, Inc. reported total revenue of $65.8 million for the three months ended March 31, 2026, marking a 40.5% increase from $46.9 million in the same period of 2025. Gross profit significantly rose to $33.701 million in Q1 2026 from $7.725 million in Q1 2025, with the gross profit margin improving to 51.2% from 16.5%. This improvement was attributed to product mix and decreased expenses following the 2025 Corporate Realignment Plan .<h4>Segment Revenue</h4><ul><li>TRILINK Segment: Revenue increased by 65.1% to $47.5 million for Q1 2026, up from $28.8 million in the prior year. This growth was primarily driven by $14.3 million from high-volume CleanCap orders for commercial phase COVID vaccine programs. Excluding these orders, TriLink’s base revenue grew 15.4% year-over-year .</li><li>CYGNUS Segment: Revenue saw a modest increase of 1.4% to $18.4 million for Q1 2026, compared to $18.1 million in the previous year, supported by strong demand in North America and EMEA .</li><li>Geographic Revenue: North America revenue was $35.689 million in Q1 2026, compared to $29.269 million in Q1 2025. Revenue from Europe, the Middle East, and Africa increased to $21.947 million from $6.878 million. Asia Pacific revenue decreased to $7.872 million from $10.557 million. Latin and Central America revenue increased to $329 thousand from $146 thousand .</li></ul><h4>Operational Metrics</h4><ul><li>Consolidated Net Loss: The net loss significantly reduced to -$6.377 million for Q1 2026 from -$52.853 million for Q1 2025. The net loss attributable to Maravai LifeSciences Holdings, Inc. was -$3.733 million in Q1 2026, an improvement from -$29.945 million in Q1 2025 .</li><li>Operating Expenses: Total operating expenses decreased by 37.0% to $35.859 million in Q1 2026 from $56.887 million in Q1 2025 .<ul><li>Selling, general and administrative (SG&amp;A) expenses decreased by 26.5% to $29.092 million in Q1 2026 from $39.564 million in Q1 2025, largely due to reductions in personnel expenses, professional services fees, stock-based compensation, facilities costs, and marketing expenses, driven by the 2025 Corporate Realignment Plan .</li><li>Research and development (R&amp;D) expenses decreased by 20.4% to $3.889 million in Q1 2026 from $4.888 million in Q1 2025, mainly due to decreases in stock-based compensation and supplies and materials, also influenced by the 2025 Corporate Realignment Plan .</li><li>Goodwill impairment was -$0 million in Q1 2026, compared to $12.435 million in Q1 2025 .</li><li>Restructuring costs were $2.878 million in Q1 2026, including -$0.4 million in severance and other employee costs .</li></ul></li><li>Adjusted EBITDA: Consolidated Adjusted EBITDA was $20.327 million for Q1 2026, a significant increase from -$10.549 million for Q1 2025 .<ul><li>TRILINK Segment Adjusted EBITDA: Increased to $17.259 million in Q1 2026 from -$8.900 million in Q1 2025 .</li><li>CYGNUS Segment Adjusted EBITDA: Increased to $13.558 million in Q1 2026 from $12.671 million in Q1 2025 .</li></ul></li><li>Interest Expense: Decreased to -$5.749 million in Q1 2026 from -$6.778 million in Q1 2025, primarily due to a voluntary prepayment of the Term Loan .</li><li>Interest Income: Decreased to $1.873 million in Q1 2026 from $3.225 million in Q1 2025, due to the use of short-term investments for the voluntary prepayment .</li><li>Income Tax (Benefit) Expense: The company recorded an income tax benefit of -$151 thousand in Q1 2026, compared to an expense of $162 thousand in Q1 2025 .</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Provided by Operating Activities: Increased to $8.665 million in Q1 2026 from net cash used of -$9.390 million in Q1 2025 .</li><li>Net Cash Used in Investing Activities: Decreased to -$4.437 million in Q1 2026 from -$23.129 million in Q1 2025 .</li><li>Net Cash Used in Financing Activities: Increased to -$55.226 million in Q1 2026 from -$4.900 million in Q1 2025, largely due to $51.4 million in principal repayments of long-term debt, including a voluntary prepayment of $50.0 million .</li><li>Cash and Cash Equivalents: Ended Q1 2026 at $165.922 million, down from $216.890 million at December 31, 2025 .</li></ul><h4>Other Key Metrics</h4><ul><li>Capital Expenditures: Totaled $1.0 million for Q1 2026 .</li><li>Long-Term Debt: The Term Loan balance was $242.880 million as of March 31, 2026, following a voluntary prepayment of $50.0 million .</li></ul><h3>Future Outlook and Strategy</h3>Maravai LifeSciences Holdings, Inc. does not anticipate further high-volume CleanCap orders for commercial phase COVID-19 vaccine programs for the remainder of 2026, expecting Q1 2026 to be the highest revenue quarter of the year. The company plans to continue investing in research and development and anticipates selling, general and administrative expenses to decrease year-over-year due to the 2025 Corporate Realignment Plan. Capital expenditures for the year ending December 31, 2026, are projected to be between $4.0 million and $6.0 million, with approximately $1.6 million in cash payments expected for restructuring costs through Q2 2026 .

Maravai LifeSciences | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 65.84 M